New Cancer Vaccine Processing Facility Comes To Jefferson

December 15, 1997

Jefferson Medical College is now home to a unique cancer vaccine processing facility. It is the only one of its kind in Philadelphia, and perhaps the nation.

AVAX Technologies, Inc., of Kansas City, Mo.--which has exclusive rights to a Jefferson-based vaccine against malignant melanoma--is building the vaccine laboratory to increase quantities of the vaccine for future testing and use. The lab is a so-called “clean lab,” which means it meets strict federal Food and Drug Administration (FDA) standards.

“If a company wants to produce a vaccine to market, the work must be done in an approved facility. It’s called a GMP--’Good Medical Practices’--lab,” explains medical oncologist David Berd, M.D., who created the vaccine technology. “It essentially will be an industrial lab in an academic facility.”

Dr. Berd, professor of medicine at Jefferson’s Kimmel Cancer Center and Jefferson Medical College, Thomas Jefferson University, and his colleagues are hoping that the $200,000 laboratory will help step up the production of the potentially life-saving cancer vaccine.

The current vaccine is autologous, meaning that it’s prepared from a patient’s own cancer cells. Each vaccine is custom-made for the patient. Before injecting the cells into patients, the cells are inactivated and treated with a chemical, dinitrophenyl, which chemically modifies them. The modified cells apparently appear foreign enough to the body’s immune system for it to react against them.

Malignant melanoma is the deadliest form of the skin cancer. It is the fastest growing cancer in the United States and is the fifth most common cancer among Americans. According to the American Cancer Society, 40,300 new cases will be diagnosed in 1997; 7300 Americans will die from the disease.

The vaccine treatment appears to be effective in prolonging the survival of patients with malignant melanoma. In the June 1997 issue of the Journal of Clinical Oncology, a leading cancer research publication, Dr. Berd reported the results of treatments on patients with melanoma spread to a single lymph node site (stage III disease). The vaccine treatments were started after the lymph nodes had been removed. Of 62 patients, 36 were still alive after a median follow-up time of 55 months. The projected 5-year relapse-free and overall survival rates for these patients were 45 percent and 58 percent respectively. This compares favorably with the 15- to 25-percent survival rates reported in patients treated with surgery alone.

Dr. Berd and his colleagues will participate in a Phase III trial to test the effectiveness of the vaccine on patients with disease that has spread to the lymph nodes. The five-year trial, already underway, will compare the effectiveness of an autologous melanoma vaccine to the standard treatment, which is alpha interferon. The trial will involve 250 patients seen at institutions in several major cities. If the trial is successful, then AVAX will ask the FDA for approval to allow it to market the vaccine.

The lab, he notes, is the first of its kind in Philadelphia and perhaps in the nation. The new lab will not be limited to vaccines for melanoma. Dr. Berd currently is testing a similar vaccine for ovarian cancer.Dr. Berd explains that many labs are working on generic cancer vaccines, but few have attempted autologous vaccines because of the technical difficulty involved in producing a vaccine for each individual patient. “We expect to show that our autologous cancer vaccine is not only effective, but also practical and applicable to large numbers of patients at sites throughout the country,” he says.
-end-


Thomas Jefferson University

Related Melanoma Articles from Brightsurf:

Boosting treatments for metastatic melanoma
University of Cincinnati clinician-scientist Soma Sengupta, MD, PhD, says that new findings from her and Daniel Pomeranz Krummel's, PhD, team might have identified a treatment-boosting drug to enhance effectiveness of therapies for metastatic cancer and make them less toxic, giving patients a fighting chance at survival and improved quality of life.

A promising new tool in the fight against melanoma
An Edith Cowan University (ECU) study has revealed that a key blood marker of cancer could be used to select the most effective treatment for melanoma.

New targets for melanoma treatment
A collaborative study led by Monash University's Biomedicine Discovery Institute and the Olivia Newton-John Cancer Research Institute (ONJCRI) has uncovered new markers (HLA-associated peptides) that are uniquely present on melanoma tumours and could pave the way for therapeutic vaccines to be developed in the fight against melanoma.

Innovative smartphone-camera adaptation images melanoma and non-melanoma
An article published in the Journal of Biomedical Optics (JBO), ''Point-of-care, multispectral, smartphone-based dermascopes for dermal lesion screening and erythema monitoring,'' shows that standard smartphone technology can be adapted to image skin lesions, providing a low-cost, accessible medical diagnostic tool for skin cancer.

Antihistamines may help patients with malignant melanoma
Can a very common allergy medicine improve survival among patients suffering from the serious skin cancer, malignant melanoma?

Blood test for deadly eye melanoma
A simple blood test could soon become the latest monitoring tool for the early detection of melanoma in the eye.

Analysis of melanoma in US by age groups
This study used registry data to determine annual rates of melanoma in pediatric, adolescent, young adult and adult age groups, and the findings suggest an apparent decrease among adolescent and young adults between 2006 and 2015 but increases in older adults.

Vitamin D dials down the aggression in melanoma cells
Vitamin D influences the behaviour of melanoma cells in the lab by making them less aggressive, Cancer Research UK scientists have found.

B cells linked to immunotherapy for melanoma
Immunotherapy uses our body's own immune system to fight cancer.

Five things to know about melanoma
'Five things to know about ... melanoma' in CMAJ (Canadian Medical Association Journal) provides a brief overview of this malignant skin cancer for physicians and patients.

Read More: Melanoma News and Melanoma Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.